Medical Doctor Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Ross Hamilton

Neurology Carlsbad, CA Medical Doctor

NPI 1538587852 CMS profile 4650473

6010 Hidden Valley Rd Ste 200, Carlsbad, CA 92011

Open in the dashboard

General payments

$5,684

240 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ross Hamilton of Carlsbad, CA is reported in the CMS Open Payments database as having received $5,684 across 240 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,415 178
2024 General $1,269 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ross Hamilton
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Ross Hamilton were reported at $4,415. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Ross Hamilton Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $0 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $1,269 $468 $119–$2,323 $164
2025 $4,415 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. AbbVie, Inc. $1,482 48 payments
  2. SK Life Science, Inc. $1,064 45 payments
  3. UCB, Inc. $906 37 payments
  4. Biogen, Inc. $340 19 payments
  5. Eisai Inc. $303 9 payments
  6. Pfizer Inc. $294 21 payments
  7. EMD Serono, Inc. $246 7 payments
  8. Lundbeck LLC $218 15 payments
  9. Neurelis, Inc. $133 6 payments
  10. Novartis Pharmaceuticals Corporation $99 5 payments
  11. Other $600 28 payments

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $5,684 240 payments
Products named General payments · program years 2024–2025
  1. UBRELVY $1,217 36 payments
  2. QULIPTA $871 31 payments
  3. Leqembi $590 25 payments
  4. Briviact $374 16 payments
  5. Nayzilam $344 13 payments
  6. NURTEC ODT $294 21 payments
  7. ZAVZPRET $294 21 payments
  8. BOTOX $200 10 payments
  9. VYEPTI $168 12 payments
  10. VALTOCO $133 6 payments
  11. Other $1,224 48 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

171

Median for Neurology: 833

Drug cost

$6,209

Median for Neurology: $202,670

Branded share of claims

10.5%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Levetiracetam Generic 27 $1,839
Divalproex Sodium Generic 34 $1,525
Zonisamide Generic 11 $1,317
Topiramate Generic 17 $438
Gabapentin Generic 19 $383
Carbidopa-Levodopa Carbidopa/Levodopa Brand 18 $215
Escitalopram Oxalate Generic 13 $212
Lamotrigine Generic 15 $159
Donepezil Hcl Generic 17 $121

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$31,582

Medicare's payments for the services billed

Medicare patients

111

Average age 75

Services billed

581

69 women, 42 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 42%
Alzheimer's or dementia 28%
Ischemic heart disease 27%
Diabetes 26%
Depression 25%
Chronic kidney disease 23%
Osteoporosis 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $204
$204 — —
QULIPTA
  • AbbVie, Inc. $155
$155 — —
Qutenza
  • Averitas Pharma Inc. $85
$85 — —
NURTEC ODT
  • PFIZER INC. $72
$72 — —
ZAVZPRET
  • PFIZER INC. $72
$72 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

240 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record